vs
FIRST CITIZENS BANCSHARES INC（FCNCA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FIRST CITIZENS BANCSHARES INC的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），FIRST CITIZENS BANCSHARES INC净利率更高（49.1% vs 12.7%，领先36.4%），Revvity同比增速更快（5.9% vs 3.5%），过去两年Revvity的营收复合增速更高（9.0% vs -33.5%）
第一公民银行控股公司是美国本土银行控股企业，总部位于罗德岛州普罗维登斯，旗下拥有国民公民银行，业务覆盖美国康涅狄格、特拉华、佛罗里达、马里兰、马萨诸塞、密歇根、新罕布什尔、新泽西、纽约、俄亥俄、宾夕法尼亚、罗德岛、佛蒙特、弗吉尼亚等14个州及华盛顿哥伦比亚特区。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FCNCA vs RVTY — 直观对比
营收规模更大
FCNCA
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出2.4%
3.5%
净利率更高
FCNCA
高出36.4%
12.7%
两年增速更快
RVTY
近两年复合增速
-33.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $534.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 49.1% | 12.7% |
| 营收同比 | 3.5% | 5.9% |
| 净利润同比 | 10.6% | 3.9% |
| 每股收益（稀释后） | $42.63 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCNCARVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $2.4B | $772.1M | ||
| Q3 25 | $2.4B | $698.9M | ||
| Q2 25 | $2.4B | $720.3M | ||
| Q1 25 | $2.3B | $664.8M | ||
| Q4 24 | $2.4B | $729.4M | ||
| Q3 24 | $2.4B | $684.0M | ||
| Q2 24 | $2.5B | $691.7M |
净利润FCNCARVTY
| Q1 26 | $534.0M | — | ||
| Q4 25 | $580.0M | $98.4M | ||
| Q3 25 | $568.0M | $46.7M | ||
| Q2 25 | $575.0M | $53.9M | ||
| Q1 25 | $483.0M | $42.2M | ||
| Q4 24 | $700.0M | $94.6M | ||
| Q3 24 | $639.0M | $94.4M | ||
| Q2 24 | $707.0M | $55.4M |
毛利率FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | 33.3% | 14.5% | ||
| Q3 25 | 30.9% | 11.7% | ||
| Q2 25 | 31.9% | 12.6% | ||
| Q1 25 | 28.3% | 10.9% | ||
| Q4 24 | 30.6% | 16.3% | ||
| Q3 24 | 35.7% | 14.3% | ||
| Q2 24 | 39.8% | 12.4% |
净利率FCNCARVTY
| Q1 26 | 49.1% | — | ||
| Q4 25 | 23.8% | 12.7% | ||
| Q3 25 | 23.3% | 6.7% | ||
| Q2 25 | 24.2% | 7.5% | ||
| Q1 25 | 21.0% | 6.4% | ||
| Q4 24 | 29.1% | 13.0% | ||
| Q3 24 | 26.1% | 13.8% | ||
| Q2 24 | 28.7% | 8.0% |
每股收益（稀释后）FCNCARVTY
| Q1 26 | $42.63 | — | ||
| Q4 25 | $45.33 | $0.86 | ||
| Q3 25 | $43.08 | $0.40 | ||
| Q2 25 | $42.36 | $0.46 | ||
| Q1 25 | $34.47 | $0.35 | ||
| Q4 24 | $49.19 | $0.77 | ||
| Q3 24 | $43.42 | $0.77 | ||
| Q2 24 | $47.54 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $34.0B | — |
| 股东权益账面价值 | $22.0B | $7.3B |
| 总资产 | $236.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.54× | — |
8季度趋势，按日历期对齐
现金及短期投资FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务FCNCARVTY
| Q1 26 | $34.0B | — | ||
| Q4 25 | $35.8B | — | ||
| Q3 25 | $38.3B | — | ||
| Q2 25 | $37.6B | — | ||
| Q1 25 | $38.0B | — | ||
| Q4 24 | $36.7B | — | ||
| Q3 24 | $36.8B | — | ||
| Q2 24 | $37.1B | — |
股东权益FCNCARVTY
| Q1 26 | $22.0B | — | ||
| Q4 25 | $22.2B | $7.3B | ||
| Q3 25 | $22.0B | $7.4B | ||
| Q2 25 | $22.3B | $7.6B | ||
| Q1 25 | $22.3B | $7.6B | ||
| Q4 24 | $22.2B | $7.7B | ||
| Q3 24 | $22.8B | $7.9B | ||
| Q2 24 | $22.5B | $7.9B |
总资产FCNCARVTY
| Q1 26 | $236.0B | — | ||
| Q4 25 | $229.7B | $12.2B | ||
| Q3 25 | $233.5B | $12.1B | ||
| Q2 25 | $229.7B | $12.4B | ||
| Q1 25 | $228.8B | $12.4B | ||
| Q4 24 | $223.7B | $12.4B | ||
| Q3 24 | $220.6B | $12.8B | ||
| Q2 24 | $219.8B | $13.4B |
负债/权益比FCNCARVTY
| Q1 26 | 1.54× | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 1.70× | — | ||
| Q4 24 | 1.65× | — | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $182.0M | ||
| Q3 25 | $916.0M | $138.5M | ||
| Q2 25 | $859.0M | $134.3M | ||
| Q1 25 | $98.0M | $128.2M | ||
| Q4 24 | $1.1B | $174.2M | ||
| Q3 24 | $991.0M | $147.9M | ||
| Q2 24 | $417.0M | $158.6M |
自由现金流FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | $807.0M | $161.8M | ||
| Q3 25 | $678.0M | $120.0M | ||
| Q2 25 | $733.0M | $115.5M | ||
| Q1 25 | $-5.0M | $112.2M | ||
| Q4 24 | $991.0M | $149.8M | ||
| Q3 24 | $885.0M | $125.6M | ||
| Q2 24 | $316.0M | $136.6M |
自由现金流率FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | 33.1% | 21.0% | ||
| Q3 25 | 27.9% | 17.2% | ||
| Q2 25 | 30.9% | 16.0% | ||
| Q1 25 | -0.2% | 16.9% | ||
| Q4 24 | 41.2% | 20.5% | ||
| Q3 24 | 36.2% | 18.4% | ||
| Q2 24 | 12.8% | 19.7% |
资本支出强度FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | 2.6% | ||
| Q3 25 | 9.8% | 2.6% | ||
| Q2 25 | 5.3% | 2.6% | ||
| Q1 25 | 4.5% | 2.4% | ||
| Q4 24 | 5.3% | 3.4% | ||
| Q3 24 | 4.3% | 3.3% | ||
| Q2 24 | 4.1% | 3.2% |
现金转化率FCNCARVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.81× | 1.85× | ||
| Q3 25 | 1.61× | 2.97× | ||
| Q2 25 | 1.49× | 2.49× | ||
| Q1 25 | 0.20× | 3.03× | ||
| Q4 24 | 1.60× | 1.84× | ||
| Q3 24 | 1.55× | 1.57× | ||
| Q2 24 | 0.59× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCNCA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
